| Clinical Takeaway | |||||||||||||||
|
The FDA has approved enlicitide, marketed as Lipfendra, the first oral inhibitor of PCSK9. Until now, blocking PCSK9 meant an injection: a monoclonal antibody every two to four weeks, or an siRNA twice a year. Enlicitide is a pill you swallow once a day.
That distinction is the whole story. PCSK9 inhibitors have worked beautifully for a decade. Most eligible patients still never get one. Injection reluctance, prescribing friction, and prior-authorization fatigue kept a proven drug class away from the people who needed it. An oral version removes the friction the biology never had.
The numbers
Across two registration trials in 3,207 statin-treated adults, enlicitide lowered LDL-C by roughly 56% in patients with or at risk for atherosclerotic disease, and by roughly 59% in those with heterozygous familial hypercholesterolemia. Both figures are placebo-adjusted at 24 weeks. That is monoclonal-antibody territory, delivered from a tablet, with a safety profile that tracked placebo. In the familial cohort, diarrhea and dizziness were reported more often than placebo. Discontinuation rates were similar between groups.
| The catchThis is an approval for lowering LDL-C, not for cutting events. Antibody PCSK9 inhibitors have proven cardiovascular benefit. Enlicitide has not, yet. Its cardiovascular outcomes trial, with more than 14,500 participants, is still running. Until it reads out, this is a drug that lowers a number extremely well, on the strong prior that the number matters. |
One more line, for the Lp(a) crowd
Buried in the secondary endpoints: enlicitide also lowered lipoprotein(a) by about 28%. That is not an indication, and no one should start this drug for Lp(a). But it is the first oral agent to move a number that statins do not touch, and it lands the same week that an oral CETP inhibitor lowering Lp(a) by 37% is under regulatory review in Europe. That is a bigger shift than a single approval.
| CORALreef program · enlicitide vs placebo, placebo-adjusted change (24 weeks) | ||||||
|
| Speculation · extrapolation beyond the data |
| If CORALreef Outcomes is positive, an oral PCSK9 inhibitor could move from a specialty add-on to something a primary care clinician reaches for right after statins and ezetimibe. Oral dosing is what turns a proven mechanism into a population-level tool. That is where this is heading if the events data hold. It is not there yet. |
The bottom line
The takeaway is narrow but real. An oral PCSK9 inhibitor does not lower LDL-C more than the injectables do. It lowers the friction that kept the injectables from most patients. If the outcomes trial confirms the events benefit, that friction reduction is what will move the numbers at scale.
| One clinical principle worth keeping: lipids and weight are one cardiometabolic system, not two clinics. At Vineyard, we treat them together. See how Vineyard works → |
Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice. Prior industry affiliations are concluded. This article is educational and is not individualized medical advice. Efficacy figures reflect the regulatory approval and phase 3 trial reports. The lipoprotein(a) effect is a secondary endpoint, not an approved indication.
REFERENCES
U.S. Food and Drug Administration. FDA approves first oral therapy that inhibits PCSK9 to lower bad cholesterol in adults with high cholesterol (enlicitide; Lipfendra). July 16, 2026. fda.gov
Navar AM, Mikhailova E, Catapano AL, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529-539. doi:10.1056/nejmoa2511002
Ballantyne CM, Gellis L, Tardif JC, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. Published online November 9, 2025. doi:10.1001/jama.2025.20620
ClinicalTrials.gov. CORALreef Outcomes: a cardiovascular outcomes trial of enlicitide decanoate. NCT06008756.
Evidence-based cardiometabolic medicine, twice a week.